Nizatidine
Axid Ar, Nizatidine (nizatidine) is a small molecule pharmaceutical. Nizatidine was first approved as Axid on 1988-04-12. It is used to treat duodenal ulcer, dyspepsia, gastroesophageal reflux, heartburn, and helicobacter infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Axid ar, Nizatidine (discontinued: Axid, Nizatidine)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nizatidine | ANDA | 2024-10-23 |
| nizatidine solution | ANDA | 2016-08-12 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastritis | D005756 | EFO_0000217 | K29.7 | 1 | — | — | 1 | — | 2 |
| Respiratory aspiration of gastric contents | D063466 | — | — | — | — | — | 1 | — | 1 |
| Weight gain | D015430 | HP_0004324 | — | — | — | — | 1 | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | 1 | — | 1 | 2 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | — | — | 1 | — | — | 1 |
| Heartburn | D006356 | — | R12 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | — | — | — | — | — | 1 | 1 |
| Hearing loss | D034381 | EFO_0004238 | H91.9 | — | — | — | — | 1 | 1 |
| Tinnitus | D014012 | HP_0000360 | H93.1 | — | — | — | — | 1 | 1 |
| Noise-induced hearing loss | D006317 | EFO_1001254 | — | — | — | — | — | 1 | 1 |
| Yin deficiency | D016710 | — | — | — | — | — | — | 1 | 1 |
| Deafness | D003638 | EFO_0001063 | H91.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nizatidine |
| INN | nizatidine |
| Description | Nizatidine is a member of the class of 1,3-thiazoles having a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl moiety at position 4. It has a role as an anti-ulcer drug, a H2-receptor antagonist and a cholinergic drug. It is a member of 1,3-thiazoles, a C-nitro compound, an organic sulfide, a tertiary amino compound and a carboxamidine. |
| Classification | Small molecule |
| Drug class | H2-receptor antagonists (cimetidine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1 |
Identifiers
| PDB | — |
| CAS-ID | 76963-41-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3183075 |
| ChEBI ID | 7601 |
| PubChem CID | 3033637 |
| DrugBank | DB00585 |
| UNII ID | P41PML4GHR (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Nizatidine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,208 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
990 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use